Envoy Medical Reports Fourth Quarter and Full Year 2024 Financial Results
Envoy Medical (NASDAQ: COCH) has released its Q4 and full-year 2024 financial results, highlighting significant progress in its pivotal clinical trial for the fully implanted Acclaim® cochlear implant. Six out of planned 10 participants have been enrolled and implanted in the trial's first stage, with two already activated.
Financial results show decreased net revenues due to reduced battery replacement sales from supply chain limitations. R&D expenses increased by $1.2 million year-over-year, primarily due to expanded headcount in engineering and clinical departments. The company ended 2024 with $5.5 million in cash and cash equivalents.
Key developments include successful completion of 24-month follow-up for Early Feasibility Trial patients, selection of seven top-tier cochlear implant programs as trial sites, and progress on the Hearing Device Coverage Clarification Act. New CPT codes for totally implantable active middle ear hearing implants will become effective in July 2025.
Envoy Medical (NASDAQ: COCH) ha pubblicato i risultati finanziari del quarto trimestre e dell'intero anno 2024, evidenziando progressi significativi nel suo studio clinico fondamentale per l'impianto cocleare Acclaim® completamente impiantato. Sei dei 10 partecipanti programmati sono stati arruolati e impiantati nella prima fase dello studio, con due già attivati.
I risultati finanziari mostrano un calo dei ricavi netti a causa della diminuzione delle vendite di sostituzione delle batterie a causa di limitazioni nella catena di approvvigionamento. Le spese per ricerca e sviluppo sono aumentate di $1,2 milioni rispetto all'anno precedente, principalmente a causa dell'aumento del personale nei dipartimenti ingegneristico e clinico. L'azienda ha chiuso il 2024 con $5,5 milioni in contante e equivalenti di cassa.
I principali sviluppi includono il completamento con successo del follow-up di 24 mesi per i pazienti dell'Early Feasibility Trial, la selezione di sette programmi di impianti cocleari di alto livello come siti di prova e progressi sulla Hearing Device Coverage Clarification Act. Nuovi codici CPT per impianti uditivi attivi totalmente impiantabili diventeranno effettivi a luglio 2025.
Envoy Medical (NASDAQ: COCH) ha publicado sus resultados financieros del cuarto trimestre y del año completo 2024, destacando avances significativos en su ensayo clínico fundamental para el implante coclear Acclaim® completamente implantado. Seis de los 10 participantes planeados han sido reclutados e implantados en la primera etapa del ensayo, con dos ya activados.
Los resultados financieros muestran una disminución de los ingresos netos debido a la reducción de las ventas de reemplazo de baterías por limitaciones en la cadena de suministro. Los gastos de I+D aumentaron en $1.2 millones en comparación con el año anterior, principalmente debido al aumento del personal en los departamentos de ingeniería y clínicos. La empresa cerró 2024 con $5.5 millones en efectivo y equivalentes de efectivo.
Los desarrollos clave incluyen la finalización exitosa del seguimiento de 24 meses para los pacientes del Early Feasibility Trial, la selección de siete programas de implantes cocleares de primer nivel como sitios de ensayo y avances en la Hearing Device Coverage Clarification Act. Nuevos códigos CPT para implantes auditivos activos totalmente implantables entrarán en vigor en julio de 2025.
Envoy Medical (NASDAQ: COCH)는 2024년 4분기 및 연간 재무 결과를 발표하며 완전 이식형 Acclaim® 인공와우의 주요 임상 시험에서 중요한 진전을 강조했습니다. 계획된 10명의 참가자 중 6명이 임상 시험의 첫 번째 단계에서 등록 및 이식되었으며, 그 중 2명이 이미 활성화되었습니다.
재무 결과는 공급망 제한으로 인한 배터리 교체 판매 감소로 인해 순매출이 감소했음을 보여줍니다. 연구개발 비용은 $1.2백만 증가했으며, 주로 엔지니어링 및 임상 부서의 인원 증가 때문입니다. 회사는 2024년을 $5.5백만의 현금 및 현금성 자산으로 마감했습니다.
주요 개발 사항으로는 조기 타당성 시험 환자에 대한 24개월 추적 조사의 성공적인 완료, 시험 사이트로서의 7개의 최고급 인공와우 프로그램 선택, 그리고 Hearing Device Coverage Clarification Act에 대한 진전이 포함됩니다. 완전 이식 가능한 활성 중이 임플란트에 대한 새로운 CPT 코드가 2025년 7월에 발효될 예정입니다.
Envoy Medical (NASDAQ: COCH) a publié ses résultats financiers du quatrième trimestre et de l'année complète 2024, mettant en évidence des progrès significatifs dans son essai clinique clé pour l'implant cochléaire Acclaim® entièrement implanté. Six des 10 participants prévus ont été recrutés et implantés lors de la première phase de l'essai, dont deux sont déjà activés.
Les résultats financiers montrent une diminution des revenus nets en raison de la réduction des ventes de remplacement de batteries en raison de limitations de la chaîne d'approvisionnement. Les dépenses de R&D ont augmenté de 1,2 million de dollars par rapport à l'année précédente, principalement en raison de l'augmentation des effectifs dans les départements d'ingénierie et clinique. L'entreprise a terminé l'année 2024 avec 5,5 millions de dollars en liquidités et équivalents de liquidités.
Les développements clés incluent l'achèvement réussi du suivi de 24 mois pour les patients de l'Early Feasibility Trial, la sélection de sept programmes d'implants cochléaires de premier plan comme sites d'essai, et des progrès sur le Hearing Device Coverage Clarification Act. De nouveaux codes CPT pour les implants auditifs actifs entièrement implantables entreront en vigueur en juillet 2025.
Envoy Medical (NASDAQ: COCH) hat seine finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 veröffentlicht und erhebliche Fortschritte in seiner entscheidenden klinischen Studie für das vollständig implantierte Acclaim®-Cochlea-Implantat hervorgehoben. Sechs der geplanten 10 Teilnehmer wurden in der ersten Phase der Studie eingeschrieben und implantiert, wobei zwei bereits aktiviert sind.
Die finanziellen Ergebnisse zeigen einen Rückgang der Nettoumsätze aufgrund reduzierter Verkäufe von Batterieersatzteilen aufgrund von Einschränkungen in der Lieferkette. Die F&E-Ausgaben stiegen im Jahresvergleich um 1,2 Millionen US-Dollar, hauptsächlich aufgrund einer erhöhten Mitarbeiterzahl in den Ingenieur- und Klinikabteilungen. Das Unternehmen schloss das Jahr 2024 mit 5,5 Millionen US-Dollar an liquiden Mitteln und Zahlungsmitteln ab.
Wichtige Entwicklungen umfassen den erfolgreichen Abschluss der 24-monatigen Nachverfolgung für Patienten der Early Feasibility Trial, die Auswahl von sieben erstklassigen Cochlea-Implantat-Programmen als Prüfstandorte und Fortschritte beim Hearing Device Coverage Clarification Act. Neue CPT-Codes für vollständig implantierbare aktive Mittelohrhörgeräte werden im Juli 2025 in Kraft treten.
- FDA approval received for pivotal clinical trial of Acclaim cochlear implant
- Strong enrollment progress with 6 out of 10 participants already implanted
- Successful 24-month follow-up for all Early Feasibility Trial patients with no adverse events
- New CPT codes approved for middle ear implants, improving reimbursement prospects
- Net revenues decreased due to supply chain limitations
- R&D expenses increased by $1.2 million year-over-year
- Sales and marketing expenses increased by $68,000
Insights
Envoy Medical's Q4 and full-year 2024 results reveal a mixed financial picture alongside significant clinical progress. The company's flagship product, the fully implanted Acclaim® cochlear implant (designated as a Breakthrough Device), shows promising advancement with 6 out of 10 participants now enrolled and implanted in the pivotal trial's first stage.
The clinical trial progression represents a critical milestone after years of development, with strong patient interest reported across investigational sites. Importantly, there have been no safety concerns reported in the early feasibility trial participants after 24 months of follow-up, suggesting a favorable safety profile.
From a financial standpoint, revenues declined year-over-year due to battery replacement supply chain constraints. R&D expenses increased by
The regulatory landscape shows promising developments with the Hearing Device Coverage Clarification Act progressing through Congress and new CPT codes approved for fully implantable active middle ear hearing implants effective July 2025. These developments could potentially unlock Medicare reimbursement for their Esteem® device, creating a stronger commercial foundation while the Acclaim implant advances through clinical trials.
Envoy Medical's financial performance reveals persistent operational challenges despite clinical advancements. Net revenues declined year-over-year primarily due to battery replacement supply chain limitations, which directly impacts the company's already modest revenue stream. More concerning is the
With cash and cash equivalents of just
The regulatory progress represents potential long-term value, particularly the advancement of the Hearing Device Coverage Clarification Act and new CPT codes for fully implantable middle ear devices. These developments could transform reimbursement prospects for the Esteem device beginning July 2025, potentially providing a revenue bridge while the Acclaim implant completes clinical evaluation.
However, without specific guidance on expected cash burn or potential capital raising plans, investors should closely monitor the company's financial position in upcoming quarters, as additional funding may be necessary to reach key commercialization milestones for the Acclaim breakthrough device.
Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Device, the Fully Implanted Acclaim® Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - March 31, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2024, as well as other subsequent events.
Brent Lucas, CEO of Envoy Medical commented: "Envoy Medical had a successful 2024 and we are off to a wonderful start in 2025. Obtaining FDA's approval to begin our pivotal clinical trial for the fully implanted Acclaim cochlear implant was a milestone many years in the making, and we are very excited to report that enrollment is going extremely well. The investigational sites are reporting a tremendous amount of patient interest in our fully implanted cochlear implant. We believe we have a special product and a great opportunity to change the hearing implant industry. We are also pleased with the progress surrounding the Hearing Device Coverage Clarification Act, which, if passed, could provide our Esteem® implant with a pathway to Medicare coverage. In addition, the establishment of new CPT codes for fully implanted active middle ear implants, which become effective in July of this year, furthered our efforts in the quest for the Esteem implant to become a reimbursed product."
Financial and Corporate Highlights for 2024 and to date:
- Continued to make modifications that have shown promising reduction in previously discussed electrical system noise (i.e., not physiological or "body noise") in initial results of the Early Feasibility Trial of the fully implanted Acclaim® cochlear implant.
- Several modifications in firmware, software, programming, protocol design, and hardware incorporated into Pivotal Clinical Trial.
- All three previously implanted Early Feasibility Trial patients have successfully completed 24 months of follow-up. No reported Unanticipated Device Events or Serious Adverse Device Effects.
- Received FDA approval to initiate a staged Pivotal Clinical Trial for its fully implanted Acclaim® cochlear implant.
- Selected seven top-tier cochlear implant programs as investigational sites for the Pivotal Clinical Trial.
- To date, six of the planned 10 participants in the Pivotal Clinical Trial's first stage have been enrolled and implanted, two of which have been activated.
- Continued to push for the bipartisan Hearing Device Coverage Classification Act, which seeks to clarify that Implanted Active Middle Ear Implants are prosthetics, not hearing aids, making them eligible for Medicare coverage. The respective bills were reintroduced in both the US House of Representatives and US Senate for the 119th Congress.
- Reported that the American Medical Association approved groundbreaking new CPT codes for totally implantable active middle ear hearing implants opening new potential opportunities for Envoy Medical's fully implanted active middle ear implant – the Esteem® device.
- Reported that it continued to increase its portfolio of patents and intellectual property.
Financial Results from YE 2024
Net revenues decreased
R&D expenses increased
Sales and marketing expenses increased
General and administrative expenses decreased
As of December 31, 2024 cash and cash equivalents were approximately
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital investments; the timing and results of IRB approvals, site documents, logistics or activations, enrollments, and clinical trials of the Acclaim CI, and the participation or any changes in participation of any institution or healthcare professionals in such trials; the Acclaim CI being the first to market fully implanted cochlear implant; the safety, performance, and market acceptance of the Acclaim CI; and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Annual Report on Form 10-K filed by Envoy Medical on March 28, 2025, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.
###
Investor Relations:
Envoy Medical Investor Relations
InvestorRelations@envoymedical.com
Media Contact:
Media@envoymedical.com
ENVOY MEDICAL, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
| December 31, 2024 | December 31, 2023 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash | $ | 5,483 | $ | 4,218 | |||
| Accounts receivable, net | 38 | 70 | |||||
| Other receivable | 780 | 176 | |||||
| Inventories | 1,708 | 1,404 | |||||
| Prepaid expenses and other current assets | 1,375 | 1,588 | |||||
| Total current assets | 9,384 | 7,456 | |||||
| Property and equipment, net | 1,275 | 351 | |||||
| Operating lease right-of-use asset (related party) | 879 | 464 | |||||
| Total assets | $ | 11,538 | $ | 8,271 | |||
| Liabilities and stockholders' deficit | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,652 | $ | 1,554 | |||
| Accrued expenses | 4,416 | 4,613 | |||||
| Other current liabilities | 573 | 645 | |||||
| Forward purchase agreement warrant liability | 472 | 4 | |||||
| Product warranty liability, current portion | 282 | 311 | |||||
| Operating lease liability, current portion (related party) | 143 | 158 | |||||
| Total current liabilities | 7,538 | 7,285 | |||||
| Term loans payable (related party) | 18,716 | — | |||||
| Product warranty liability, net of current portion | 1,771 | 1,923 | |||||
| Operating lease liability, net of current portion (related party) | 802 | 404 | |||||
| Publicly traded warrant liability | 662 | 332 | |||||
| Forward purchase agreement put option liability | — | 103 | |||||
| Other liability | 891 | — | |||||
| Total liabilities | 30,380 | 10,047 | |||||
| Commitments and contingencies (see Note 16) | |||||||
| Stockholders' deficit: | |||||||
| Series A Preferred Stock, | |||||||
| 10,000,000 shares designated as of December 31, 2024 and 2023; 4,126,667 and 4,500,000 shares issued and outstanding as of December 31, 2024 and 2023, respectively | — | — | |||||
| Class A Common Stock, | |||||||
| December 31, 2024 and 2023; 21,326,609 and 18,599,982 shares issued and outstanding as of December 31, 2024 and 2023, respectively | 2 | 2 | |||||
| Additional paid-in capital | 266,013 | 255,596 | |||||
| Accumulated deficit | (284,734) | (257,256 | |||||
| Accumulated other comprehensive loss | (123) | (118) | |||||
| Total stockholders' deficit | (18,842) | (1,776) | |||||
| Total liabilities and stockholders' deficit | $ | 11,538 | $ | 8,271 |
ENVOY MEDICAL, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share amounts)
| Year Ended December 31, | |||||||||
| 2024 | 2023 | ||||||||
| Net revenues | $ | 225 | $ | 316 | |||||
| Costs and operating expenses: | |||||||||
| Cost of goods sold | 742 | 789 | |||||||
| Research and development | 10,179 | 8,956 | |||||||
| Sales and marketing | 1,734 | 1,666 | |||||||
| General and administrative | 6,826 | 7,264 | |||||||
| Total costs and operating expenses | 19,481 | 18,675 | |||||||
| Operating loss | (19,256) | (18,359) | |||||||
| Other income (expense): | |||||||||
| Change in fair value of convertible notes payable (related party) | — | (13,332) | |||||||
| Change in fair value of forward purchase agreement put option liability | 103 | (69) | |||||||
| Change in fair value of forward purchase agreement warrant liability | 411 | 842 | |||||||
| Change in fair value of forward purchase agreement warrant liability due to modification | (881) | — | |||||||
| Change in fair value of publicly traded warrant liability | (330) | 942 | |||||||
| Interest expense, related party | (816) | — | |||||||
| Other (expense) income | (26) | 54 | |||||||
| Total other expense, net | (1,539) | (11,563) | |||||||
| Net loss | (20,795) | (29,922) | |||||||
| Induced conversion of Series A Preferred Stock into Class A Common Stock | (1,162) | — | |||||||
| Deemed dividend on waiver of restriction on Class A Common Stock | (495) | — | |||||||
| Cumulative preferred dividends | (5,521) | (1,349) | |||||||
| Net loss attributable to common stockholders, basic and diluted | $ | (27,973) | $ | (31,271) | |||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (1.49) | $ | (2.54) | |||||
| Weighted-average Class A Common Stock outstanding, basic and diluted | 18,790,448 | 12,295,391 | |||||||
| Other comprehensive loss: | |||||||||
| Foreign currency translation adjustment | (5) | (3) | |||||||
| Other comprehensive loss | (5) | (3) | |||||||
| Comprehensive loss | $ | (20,800) | $ | (29,925) | |||||
ENVOY MEDICAL, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
| Year Ended December 31, | |||||||||||
| 2024 | 2023 | ||||||||||
| Cash flows from operating activities | |||||||||||
| Net loss | $ | (20,795) | $ | (29,922) | |||||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||
| Depreciation | 173 | 133 | |||||||||
| Interest expense and amortization of debt discount on term loans payable (related party) | 816 | — | |||||||||
| Amortization of prepaid insurance | 1,047 | 602 | |||||||||
| Stock-based compensation | 562 | 1,575 | |||||||||
| Change in fair value of convertible notes payable (related party) | — | 13,332 | |||||||||
| Change in fair value of warrant liability (related party) | — | (127) | |||||||||
| Change in fair value of publicly traded warrant liability | 330 | (942) | |||||||||
| Change in fair value of forward purchase agreement warrant liability | (411) | (842) | |||||||||
| Change in fair value of forward purchase agreement put option liability | (103) | 69 | |||||||||
| Change in fair value of forward purchase agreement warrant liability due to modification | 881 | — | |||||||||
| Change in operating lease right-of-use asset (related party) | 113 | 113 | |||||||||
| Change in inventory reserve | 76 | (99) | |||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable, net | 32 | (29) | |||||||||
| Other receivable | (604) | (176) | |||||||||
| Inventories | (380) | (10) | |||||||||
| Prepaid expenses and other current assets | 9 | (853) | |||||||||
| Accounts payable | (19) | 551 | |||||||||
| Operating lease liability (related party) | (145) | (128) | |||||||||
| Accrued expenses | (241) | (94) | |||||||||
| Product warranty liability | (181) | (244) | |||||||||
| Other liability | 891 | — | |||||||||
| Net cash used in operating activities | (17,949) | (17,091) | |||||||||
| Cash flows from investing activities | |||||||||||
| Purchases of property and equipment | (980) | (153) | |||||||||
| Net cash used in investing activities | (980) | (153) | |||||||||
| Cash flows from financing activities | |||||||||||
| Proceeds from the issuance of convertible notes payable (related party) | — | 10,000 | |||||||||
| Proceeds from the issuance of Common Stock | — | 109 | |||||||||
| Proceeds from the PIPE Transaction, the forward purchase agreement, and the Business Combination, net of transaction costs | — | 11,736 | |||||||||
| Payments on insurance financing loans | (916) | (563) | |||||||||
| Proceeds from the issuance of term loans (related party) | 20,000 | — | |||||||||
| Dividends paid to stockholders of Series A Preferred Stock | (2,447) | — | |||||||||
| Proceeds from issuance of Common Stock under employee stock purchase plan | 63 | — | |||||||||
| Proceeds from exercise of forward purchase agreement warrants | 1,815 | — | |||||||||
| Proceeds from the sale of Common Stock associated with forward purchase agreement, net of transaction costs | 1,683 | — | |||||||||
| Net cash provided by financing activities | 20,198 | 21,282 | |||||||||
| Effect of exchange rate changes on cash | (5) | (3) | |||||||||
| Net increase in cash | 1,265 | 4,035 | |||||||||
| Cash, beginning of year | 4,218 | 183 | |||||||||
| Cash, end of year | $ | 5,483 | $ | 4,218 | |||||||
| Supplemental disclosures of cash flow information: | |||||||||||
| Cash paid for interest | $ | 41 | $ | 26 | |||||||
| Cash paid for income taxes | $ | — | $ | — | |||||||
| Non-cash investing and financing activities: | |||||||||||
| Property and equipment purchased on account | $ | 117 | $ | — | |||||||
| Financing of prepaid insurance | $ | 843 | $ | 1,115 | |||||||
| Deemed capital contribution from related party | $ | — | $ | 18,702 | |||||||
| Accrued and unpaid dividends on Series A Preferred Stock | $ | 3,074 | $ | 1,349 | |||||||
| SPAC excise tax liability recognized upon the Business Combination | $ | — | $ | 2,248 | |||||||
| Warrants issued with term loans (related party) | $ | 1,397 | $ | — | |||||||
| Convertible debt exchanged for equity | $ | — | $ | 27,493 | |||||||
| Bridge note exchanged for equity | $ | — | $ | 10,982 | |||||||
| Series A Preferred Stock issued to PIPE investor in connection with the Merger | $ | — | $ | 10,000 | |||||||
| Prepaid forward purchase agreement | $ | — | $ | 1,384 | |||||||
| Extinguishment of excess warrant liability upon exercise of warrants associated with the forward purchase agreement | $ | 96 | $ | — | |||||||
| Modification of forward purchase agreement warrant liability | $ | 94 | $ | — | |||||||
| Waiver of accrued dividends associated with Sponsor Support Agreement | $ | 3,733 | $ | — | |||||||
| Deemed dividend on waiver of restriction on Class A Common Stock | $ | 495 | $ | — | |||||||
| Induced conversion of Series A Preferred Stock to Common Stock | $ | 1,162 | $ | — | |||||||
| Lease liability arising from obtaining right-of-use asset | $ | 528 | $ | — | |||||||
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/246538
FAQ
How many participants have been enrolled in COCH's Acclaim cochlear implant Pivotal Clinical Trial?
What caused Envoy Medical's (COCH) revenue decrease in 2024?
How much cash does Envoy Medical (COCH) have as of December 31, 2024?
What is the status of COCH's Early Feasibility Trial patients?
When will the new CPT codes for COCH's implantable hearing devices become effective?
